Can IVUS Define Plaque Features that Impact Patient Care?

Similar documents
The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Cardiovascular Research Foundation and Columbia University Medical Center, New York.

Imaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Assessment of Vulnerable Plaque by IVUS and VH-IVUS

Imaging Atheroma The quest for the Vulnerable Plaque

2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:

OCT Findings: Lesson from Stable vs Unstable Plaques

Pathology of Vulnerable Plaque Angioplasty Summit 2005 TCT Asia Pacific, Seoul, April 28-30, 2005

Optical Coherence Tomography for Intracoronary Imaging

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy

Plaque Characteristics in Coronary Artery Disease. Chourmouzios Arampatzis MD, PhD, FESC

Gary S. Mintz,, MD. IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function

Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection

Left main coronary artery (LMCA): The proximal segment

Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington.

Added Value of Invasive Coronary Imaging for Plaque Rupture and Erosion

1st Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece

as a Mechanism of Stent Failure

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Usefulness of OCT during coronary intervention

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

Can We Identify Vulnerable Patients & Vulnerable Plaque?

Assessment of plaque morphology by OCT in patients with ACS

Pathology of Coronary Artery Disease

Failure of positive. Recanalization and CTO formation. TCFA rupture with (fatal) thrombotic occlusion. TCFA Lipid pool

Coronary Artery Thermography

Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation

IVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea

Invasive Imaging (IVUS, VH-IVUS, and OCT): How I Implement into My

State of the Art. Advances in Cardiovascular Imaging. ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC

Strategies for PCI of SVG

대한심장학회춘계학술대회 Satellite Symposium

Vulnerable Plaque Pathophysiology, Detection, and Intervention. VP: A Local Problem or Systemic Disease. Erling Falk, Denmark

Assessment of vulnerable plaque by OCT

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Insights in Thrombosis and In-Stent Restenosis

High-risk vulnerable plaques. Kostis Raisakis G.Gennimatas General Hospital of Athens

IVUS vs FFR Debate: IVUS-Guided PCI

CASE from South Korea

Cottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?

Between Coronary Angiography and Fractional Flow Reserve

FESC, FACC, MAHA, MSCAI, MEAPSI, ESH

Que nos puede aportar el OCT intracoronario

Cardiac CT Angiography

Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Catch-up Phenomenon: Insights from Pathology

Percutaneous Intervention of Unprotected Left Main Disease

Invasive Evaluation of High Risk or Vulnerable Plaque A Powerful Tool to Address Potential Pharmacological Agents? Jagat Narula, MD PhD MACC

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

PCI for Long Coronary Lesion

Integrated Use of IVUS and FFR for LM Stenting

Non-invasive Plaque Imaging

OCT GUIDED TREATMENT OF CALCIFIED LESIONS RICHARD SHLOFMITZ, MD CHAIRMAN OF DEPT. OF CARDIOLOGY ST. FRANCIS HOSPITAL ROSLYN, NEW YORK

Sites of Atherosclerosis In order of Frequency

Intervention: How and to which extent is technology helping us?

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

Defining Plaque Composition by CTA: The Latest Tool to Monitor Therapy?

Debate Should we use FFR? I will say NO.

FFR= Qs/Qn. Ohm s law R= P/Q Q=P/R

The Dynamic Nature of Coronary Artery Lesion Morphology Assessed by Serial Virtual Histology Intravascular Ultrasound Tissue Characterization

Basics of Angiographic Interpretation Analysis of Angiography

Optimal assessment observation of intravascular ultrasound

The Future of intravascular Is there light or sound at the end of the tunnel? Hybrid Imaging

Dynamic Nature of Nonculprit Coronary Artery Lesion Morphology in STEMI

New Insight about FFR and IVUS MLA

PCI for In-Stent Restenosis. CardioVascular Research Foundation

Noninvasive Coronary Imaging: Plaque Imaging by MDCT

Chapter 43 Noninvasive Coronary Plaque Imaging

FFR-guided Jailed Side Branch Intervention

Unprotected LM intervention

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Role of Intravascular Ultrasound in Patients with Acute Myocardial Infarction

Malaysian Healthy Ageing Society

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014

CPIS So-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of MedicineSuwon, Korea

CT Imaging of Atherosclerotic Plaque. William Stanford MD Professor-Emeritus Radiology University of Iowa College of Medicine Iowa City, IA

What Stent to Use? JASVINDAR SINGH MD, FACC

Quick guide. Core. precision guided therapy system

Smooth muscle pharmacology & interventional cardiology

Quinn Capers, IV, MD

LM stenting - Cypher

PCI for Bifurcation Coronary Lesion

Left Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD

Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013

RESTENOSIS Facing up to the problem

ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study

In-Stent Restenosis. Can we kill it?

Controversies in Coronary Revascularization. Atlanta CCU April 15, 2016

PCI for Left Anterior Descending Artery Ostial Stenosis

From the Vulnerable Atherosclerotic Plaque to CAD Management

DES In-stent Restenosis

Review Article Optical Coherence Tomography Imaging in Acute Coronary Syndromes

Fielder XT: Initial and. Department of Cardiology, Asan Medical Center, Ulsan University of college of medicine

Potential recommendations for CT coronary angiography in athletes

IVUS Virtual Histology. Listening through Walls D. Geoffrey Vince, PhD The Cleveland Clinic Foundation

Jose Mª de la Torre Hernandez, MD, PhD, FESC. Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander. SPAIN

Transcription:

Can IVUS Define Plaque Features that Impact Patient Care? A Pichard L Satler, K Kent, R Waksman, W Suddath, N Bernardo, N Weissman, M Angelo, D Harrington, J Lindsay, J Panza. Washington Hospital Center Washington DC

Conflict of Interest None related to this presentation

IVUS at the WHC Washington Hospital Center in last 12 months: Diagnostic catheterizations: 10,000 Coronary angioplasties: 5,000 IVUS use: 70% (AP: 95%) Organization 10 Labs: 8 Labs have IVUS integrated into the Cath Table (Volcano and Boston). IVUS setup is ready before physician arrives into the room. 2 CV technicians supervise all IVUS cases. 15 CV technicians trained in IVUS. Core Lab analyzes of all IVUS data.

Vessel Size Remodeling.

Positive Remodeling: large plaque mass. plaque is soft. more likely to have thrombus. associated with higher CRP. More common in young people. Very common in acute coronary syndrome. More common no reflow during PCI. Negative Remodeling: less plaque mass plaques are fibrotic. less likely to have thrombus.

Erosion Stable Thin cap atheroma Plaque hemorrhage Acute rupture Healed rupture Total occlusion IEL-Expected IEL (/plaque area) Remodeling in Varying Coronary Lesion Morphologies Macrophage infiltration Posit Remodeling A. 5 4 3 2 1 0-1 -2-3 NC Medial SMC loss SMC loss Medial SMC apoptosis Virmani 2009

Cardiac CT can be as good as IVUS to detect Positive Remodeling

Positive Remodeling and Plaque Composition by OCT. Raffel et al. EHJ 2008;29:1721-8

Positive Remodeling and ISRS Okura et al. JACC 2001, 37: 1031-35 n= 108 BMS Positive Remodeling Intermed. or Negative Remodeling

Plaque Burden and In-Stent Intimal Hyperplasia WHC: Shiran et al, AJC 2000; 86:1318-21 Maximal IH at 6 months angio was at the zone of maximal pre intervention plaque. Pre-intervention plaque area was an independent predictor of IH at follow up.

Remodeling and ISRS in DES. Mintz, Park et al. Circulation. 2003;108:1295-8 ASPECT (ASian Paclitaxel-Eluting Stent Clinical Trial) positive intermed negative Cypher RS 28.6% vs 16.7% for positive and non posit remodeling p=ns. AHA 2009

Mild LMCA Disease and Remodeling. WHC: YJ Hong et al. JIC 2007;19:500-5 236 patients with mild (<50%) LMCA stenosis by angiography 1 year MACE

Positive Remodeling and Outcome in ACS. Okura, Mintz et al. AJC 2009;103:791-5

Prospect. MACE in Non Culprit Lesions

Attenuated Plaque (Black Holes, Echo Signal Attenuation) WHC: SY Lee, Mintz et al. JACC Interv 2009;2:65-72 Shadowing in spite of no visible calcium Two attenuated plaques 6.4 mm apart were seen in this RCA.

Attenuated Plaque in ACS. WHC: SY Lee, Mintz et al. JACC Interv 2009;2:65-72 293 ACS patients: 26% with attenuated plaque ( 40% STEMI, 18% NSTEMI) Attenuated plaque in ACS patients was associated with: - positive remodeling and higher CRP, - more thrombus and complex lesion morphology, - more plaque burden and plaque rupture, - frequent no-reflow after PCI.

Echo Signal Attenuation (EA). Kimura et al. Circ CV Interv. 2009;2:444-54. 687 patients. EA: 43.8% in ACS vs. 27.9% in Stable AP, p<0.001. EA had Positive Remodeling: 55% vs 23 % for lesions without EA. Histology after DCA: higher prevalence of lipid-rich plaque, macrophage infiltration, cholesterol clefts, thrombus, and microcalcification.

No Reflow in SVG s with ACS. WHC: YJ Hong et al. TCT 06

IVUS images of the same cross section of coronary artery at baseline (left) and follow-up (right). The presence of a large branch at 10 o clock and a smaller branch at 7 o clock confirms that the same matched cross section has been studied at the 2 time points. Plaque Regression by IVUS Tardif et al. AJC 2006;98:2327 Intense Lipid Therapy x 2 years in 432 lesions <50%. Baseline IVUS IVUS at 24 months

Change in in area (mm2) Change in area (mm2) Progression of Disease in SVG WHC: YJ Hong JACC 2009;53:1257-64

Summary Positive remodeling with large plaque burden is an important observation that determines clinical and PCI outcomes.

CALCIFIED LESIONS

Patient with Angina and LAD Perfusion Defect Simple PCI?

IVUS of LAD In view of IVUS findings Roto-DES or LIMA need to be chosen

Different Strategies based on IVUS findings Direct Stenting A 5 m m Roto-Stent B

Concealed Vessel Perforation

Most Perforations are Not Seen by Angio. Maehara et al. WHC 2001 15,000 IVUS reviewed 76 perforations found on IVUS. Angio: 21% totally normal 33% dissections 22% mild stenosis 24% perforation suspected 12 months Follow up 30% MACE

Virtual Histology (A) Pathological intimal thickening. (B) Thin-capped fibroatheroma. (C) Thick-capped fibroatheroma. (D) Fibrotic plaque. (E) Fibrocalcific plaque.

The PROSPECT Trial IVUS of culprit lesion + 2 non culprit vessels 700 pts with ACS QCA of entire coronary tree IVUS with Virtual histology Palpography (n=~350) Meds rec Aspirin Plavix 1yr Statin Repeat biomarkers @ 30 days, 6 months F/U: 1 mo, 6 mo, 1 yr, 2 yr, 3-5 yrs MSCT Substudy N=50-100 Repeat imaging in pts with events

MACE (%) PROSPECT: MACE 25 20 All 20.4% 15 10 Culprit Lesion Non Culprit Les. 12.9% 11.6% 5 0 Number at risk 0 1 2 3 Time in Years ALL 697 557 506 480 CL related 697 590 543 518 NCL related 697 595 553 521 Indetermina Indeterminate 2.7%

Plaque Burden, VH and Outcomes MACE in non Culprit lesions A 70% plaque burden lesion by gray scale IVUS has a risk of 9.2% at three years A 70% plaque burden lesion defined as VH TCFA has an elevated risk of 15.3% at three years A 70% plaque burden lesion defined as PIT has a reduced risk of only 2.6% at three years VH Definitions in PROSPECT can swing the risk profile The same lesions by grayscale IVUS (Plaque Burden 70%) have dramatically different risk profiles when looking at VH

Dynamic Nature of Plaque by VH. Kubo, Maehara et al. JACC 2010;55:1590-7 Stable Progressive ACTIVE

Stenting and Plaque by VH. Koenig, Margolis, Virmani, Klaus. Nature Clinical Practice 2008 5;4 Koenig, Margolis, Virmani, Klaus. Nature Clinical Practice 2008 5;4

Stent in AMI Darius Dudek. TCT 2009 40% NC covered 50% NC uncovered 10% Distal segment Proximal segment

Plaque Healing after Stenting Kubo et al. Am Heart J. 2010;159:271-7. Necrotic Core in contact with stent before and after Stenting DES BMS

Conclusions Plaque characterization by IVUS allows for: Better PCI planning and execution. Better PCI outcome. Better prediction of near and long term outcome. Better delineation of need for optimal medical therapy for that lesion. Better understanding of Coronary Atherosclerosis.

The end